QNRX: Quoin Pharmaceuticals Ltd. Company Value to Net Income

Corporate emblem and logo of Quoin Pharmaceuticals Ltd (QNRX)

Quoin Pharmaceuticals develops advanced therapies for rare skin pathologies, addressing the deficiency of vital proteins within the framework of precision medicine. The brand's impeccable reputation and the trust of the scientific community confirm the ethics of its clinical trials. The company's price evolution, where the PE ratio stands at -0.90, demonstrates the resilience of a business striving to green its laboratory processes and reduce harmful emissions.

Quoin Pharma (QNRX) Price to Earnings Ratio: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Quoin Pharmaceuticals

- market capitalization information:
Comprehensive company analysis:QNRX - Quoin Pharma
Manufactured product of quoinpharma.com

Quoin Pharmaceuticals (QNRX) operates in a niche segment of rare dermatological pathologies. The ratio of market value to net income allows for an assessment of the investor's premium paid for every dollar of earnings. By analyzing the company's P/E multiplier history, one can determine the degree of asset overvaluation. For a biotech firm with binary risks, this indicator reveals the balance between valuation and pipeline potential. Low values here may signal stagnation in technological development.